C4 Therapeutics (CCCC) Net Cash Flow Growth (1y) (2020 - 2026)
C4 Therapeutics (CCCC) Net Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 301.06% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | C4 Therapeutics | 460.17 Mn | 224.50 Mn | - | -216.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -216.90% |
| Dec 31, 2025 | 480.58% |
| Sep 30, 2025 | -43.69% |
| Jun 30, 2025 | 262.37% |
| Mar 31, 2025 | 88.61% |
| Dec 31, 2024 | -106.33% |
| Sep 30, 2024 | -182.79% |
| Jun 30, 2024 | -260.07% |
| Mar 31, 2024 | -287.26% |
| Dec 31, 2023 | 431.40% |
| Sep 30, 2023 | 310.01% |
| Jun 30, 2023 | -140.69% |
| Mar 31, 2023 | 165.48% |
| Dec 31, 2022 | 76.60% |
| Sep 30, 2022 | 93.46% |
| Jun 30, 2022 | -93.89% |
| Mar 31, 2022 | 65.31% |
| Dec 31, 2021 | -171.53% |
| Sep 30, 2021 | -167.77% |
| Jun 30, 2021 | 447.19% |